Company: ICUI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000883984-25-000007
Chunk: 348

Company: ICU MEDICAL INC/DE
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 348
---
42023Finance leasesOther assets$3,259$2,707Accrued liabilities$1,066$860Other long-term liabilities2,3321,954Total finance lease liabilities$3,398$2,814Weighted-Average Remaining Lease TermFinance leases3.5 years4.1 yearsWeighted-Average Discount RateFinance leases5.63 %4.93 %    As of December 31, 2024, the maturities of our operating and finance lease liabilities for each of the next five years are approximately (in thousands):

Operating LeasesFinance Leases2025$17,996 $1,215 202613,506 1,104 20279,093 759 20286,612 420 20295,280 197 Thereafter11,620 47 Total Lease Payments64,107 3,742 Less imputed interest(7,635)(344)Total$56,472 $3,398     

NOTE 8. SHARE-BASED AWARDS

 We have a stock incentive plan for employees and directors and an employee stock purchase plan; however, the employee stock purchase plan was suspended in 2017. Shares to be issued under these plans will be issued either from authorized but unissued shares or from treasury shares.We incur stock compensation expense for stock options, restricted stock units ("RSU") and performance restricted stock units ("PRSU"). We receive a tax benefit on stock compensation expense and direct tax benefits from the exercise of stock options and vesting of restricted stock units. We also have had indirect tax benefits upon exercise of stock options and vesting of restricted stock units related to research and development tax credits which are recorded as a reduction of income tax expense.  The table below summarizes compensation costs and related tax benefits (in thousands): Year ended December 31,202420232022Stock compensation expense$46,883 $40,563 $36,025 Tax benefit from stock-based compensation cost$5,524 $5,379 $4,636 Indirect tax benefit$— $— $749 

89

ICU MEDICAL, INC. AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

As of December 31, 2024, we had $55.3 million of unamortized stock compensation cost which we will recognize as an expense over a weighted-average period of